

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: DREYFUS et al.
Appl. No.: New Group: Unknown
Filed: August 5, 2003 Examiner: Unknown
For: MUTANT *E. COLI* STRAINS, AND THEIR USE
FOR PRODUCING RECOMBINANT POLYPEPTIDES

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Date: August 5, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).

09/762,481

U.S. Filing Date(s)

February 7, 2001

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 25-0120.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

YOUNG & THOMPSON

By Philip A. DuBois
Philip A. DuBois, #50,696

PD/psf

745 South 23rd Street
Arlington, Virginia 22202
(703) 521-2297

Enclosures: ☒ PTO-1449
☐ References
☐ Foreign Search Report
☐ Other:

(Rev. 04/19/2000)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Attorney Docket No.: 0508-1042-1	Application No.: NEW
	Applicant: DREYFUS et al.	
	Filing Date: August 5, 2003	Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP 0 178 863	Apr. 1986	EUROPEAN				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	I. IOST et al., "The stability of Escherichia coli lacZ mRNA depends upon the simultaneity of its synthesis and translation", <i>EMBO JOURNAL</i> , Vol. 13, No. 13, 1995, pp. 3252-3261
	M. KIDO et al., "RNase E polypeptides lacking a carboxyl-terminal half suppress a mukB mutation in Escherichia coli", <i>JOURNAL OF BACTERIOLOGY</i> , Vol. 178, No. 13, July 1996, pp. 3917-3925
	I. IOST, "Couplages entre la synthèse..." PASCAL NO.: 97-0507561, <i>INIST, CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)</i> , May 1995
	K.J. McDOELL et al., "The N-terminal domain of the rne gene-product has RNase E-activity and its non-overlapping with the Arginine-rich RNA-binding site", <i>JOURNAL OF MOLECULAR BIOLOGY</i> , Vol. 255, No. 3, January 26, 1996, pp. 349-355
	P.J. LOPEZ et al., "The C-terminal half of the RNase E, which organizes the Escherichia coli degradosome, participates in mRNA degradation but not rRNA processing in vivo", <i>MOLECULAR MICROBIOLOGY</i> , Vol. 33, No. 1, July 1999, pp. 188-199
	Cohen, S.N., et al. (1997) <i>Mol. Microbiol.</i> 23(6), 1099-1106

EXAMINER:	DATE CONSIDERED
-----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* Abstract provided for the Examiner's convenience